The American and the European guidelines suggest the use of sacubitril or ACE inhibitors (ACEis) and beta-blockers (BBs) as standard heart failure therapy for symptomatic patients with reduced ejection fraction (HFrEF), independent of the etiology and combined with mineralo-receptor antagonists and SGLT2 inhibitors [13,14]. Here, SLC5A2 is linked to heart failure.